Strategic Partnerships Potential sales opportunities exist in expanding collaborations with pediatric and orthopedic players like OrthoPediatrics, as evidenced by their partnership to integrate robotic-assisted cochlear implant technology, suggesting a receptive ecosystem for co-development and distribution agreements.

Clinical Validation Leverage the FDA-cleared iotaSOFT insertion system and cited 2026 Laryngoscope data showing better hearing preservation with robotic insertion to target implant centers focused on outcomes-driven procurement and surgeon preference for minimally traumatic procedures.

Board & Advisory Momentum Recent board appointments and an expanded scientific advisory board signal growth readiness; engage executive search and advisory channels to identify strategic buyers, partners, and potential acquisition conversations with mid-market medical device firms.

Funding & Scale With substantial funding and a Series A in 2023 plus ongoing investor interest, pursue opportunities with investors or portfolio companies in the medical robotics and implant space, particularly those seeking to add robotic-assisted CI capabilities to their offerings.

Global Clinic Adoption Target high-volume cochlear implant centers and global clinics prioritizing precision robotics in surgery; emphasize workflow compatibility, patient-mounted robot design, and reduced intraoperative trauma to drive adoption in hospital systems and ambulatory surgery networks.